Apr 08, 2019
IGF Oncology Appoints Gary G. Altman, Ph.D., as Chief Executive Officer
Feb 11, 2019
GWU'S DR. PATRICIA BERG TO TELL AMER ASSN. FOR ADVANCEMENT OF SCIENCE: NOVEL GENE GIVES "PROMISE FOR PROGNOSIS AND TREATMENT OF MANY CANCERS" -- SAT., FEB 16, 3:30 pm, Wash. DC, Marriott Wardman Park--Flash Talk Stage
Jan 29, 2019
Cognitive Clarity Inc. Launches Percepta Sport(TM) and Earns International Certification for Sport® from NSF
Jan 09, 2019
KARMET Study Begins Enrollment
Jan 07, 2019
Integral Molecular Enters Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo
Jan 03, 2019
REVOLUTION Medicines to Present at the J.P. Morgan Healthcare Conference on January 8, 2019
Dec 13, 2018
Cognitive Clarity Inc. Expands Successful Product Line with Launch of Percepta Professional(TM) at the 26th Annual World Congress on Anti-Aging Medicine 2018
Dec 01, 2018
Petra Pharma Presents Preclinical PIP4K2 Inhibitor Data as a Potential Treatment for Hematologic Malignancies at the 2018 American Society of Hematology Annual Meeting
Nov 29, 2018
Tuberous Sclerosis Alliance Preclinical Consortium Announces New Staff and Company Members
Nov 15, 2018
Torrey Pines Investment's i2020 Accelerator to Advance Snap Bio's Selective Kinase Inhibitor Platform for Treatment of Endodermal Cancers and Autoimmune Diseases
Oct 02, 2018
CureLab Oncology publishes proof of concept demonstrating that its product can reduce the leading cause of age-related blindness
Aug 28, 2018
Neurotrope Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018
Aug 10, 2018
Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics
May 30, 2018
Chrysanthy Tsakopoulos Demos Named President & CEO Of AKT Investments Inc., Northern California's Largest Land Development Company
Apr 30, 2018
Tuberous Sclerosis Complex Global Awareness Day Scheduled for May 15
Apr 26, 2018
Bio-Techne Leads the Way in Scientific Support for Autophagy Research
Apr 10, 2018
Tuberous Sclerosis Alliance salutes FDA approval of Afinitor® DISPERZ (everolimus) as the first adjunctive treatment approved in US for patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures
Apr 10, 2018
Novartis drug Afinitor DISPERZ® receives FDA approval to treat TSC-associated partial-onset seizures